NOTICE OF CHANGE IN CORPORATE STRUCTURE

Section 4.9 of National Instrument 51-102
Continuous Disclosure Obligations

Item 1. Names of the parties to the transaction

EVP Capital Inc. (the "**Corporation**")
Sharp Edge Labs, Inc. ("**Sharp**")
SEL AcquisitionCo Inc. ("**Subco**")

Item 2. Description of the transaction

On December 11, 2024, the Corporation completed the acquisition of all of the issued and outstanding securities of Sharp constituting its "Qualifying Transaction" (within the meaning of the policies of the TSX Venture Exchange) (the "**Qualifying Transaction**").

The Qualifying Transaction was completed by way of a court-approved plan of arrangement under the *Business Corporations Act* (Ontario) ("**OBCA**") pursuant to which the Corporation acquired all of the issued and outstanding shares of Sharp, an arm's length third party, by way of merger conducted under the Delaware General Corporation Law in which Subco merged with and into Sharp, as part of a plan of arrangement (the "**Arrangement**"). Following the Arrangement, the Corporation continued under the name "Sharp Therapeutics Corp." (the "**Resulting Issuer**"). The Arrangement, including the name change, was approved by the shareholders of the Corporation at an annual and special meeting of shareholders held on December 6, 2024.

Pursuant to the Arrangement, each issued and outstanding share of common stock in the capital of Sharp (each a "**Sharp Share**") was exchanged for common shares of the Resulting Issuer, (the "**Resulting Issuer Shares**") on the basis of approximately 31.21940 Resulting Issuer Shares for one (1) Sharp Share (the "**Exchange Ratio**") such that all holders of Sharp Shares became shareholders of the Resulting Issuer and Sharp Edge became a wholly-owned subsidiary of the Resulting Issuer upon completion of the Arrangement. In addition, all securities convertible, exercisable or exchangeable into Sharp Shares outstanding at the effective time was exchanged for similar securities of the Resulting Issuer on the basis of the Exchange Ratio.

As a result of the Arrangement, as at December 11, 2024, there were 282,208,481 Resulting Issuer Shares outstanding, of which 273,663,281 Resulting Issuer Shares, representing approximately 97.0% of the currently outstanding Resulting Shares, were held by the former shareholders of Sharp. In addition, as at December 11, 2024, an aggregate of 33,167,424 Resulting Issuer Shares were reserved for issuance to former holders of stock options of Sharp, former holders of warrants of Sharp, pre-existing stock options of the Corporation and pre-existing warrants of the Corporation.

Item 3. Effective date of the transaction

December 11, 2024

Item 4. Name of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity

Sharp Therapeutics Corp. is the continuing entity.

Item 5. Date of the reporting issuer's first financial year-end after the transaction

December 31, 2024

Item 6. Periods, including comparative periods, if any, of the interim financial reports and the annual financial statements required to be filed for the reporting issuer's first financial year after the transaction

Audited annual financial statements of the Corporation for the financial year ended December 31, 2024, including comparative financial information for the period ended December 31, 2023.

Consolidated interim financial statements of the Corporation for the three months ended March 31, 2025, including comparative financial information for the period ended March 31, 2024.

Consolidated interim financial statements of the Corporation for the six months ended June 30, 2025, including comparative financial information for the period ended June 30, 2024.

Consolidated interim financial statements of the Corporation for the nine months ended September 30, 2025, including comparative financial information for the period ended September 30, 2024.

Item 7. Documents filed under National Instrument 51-102 – *Continuous Disclosure Obligations* that describe the transaction and where those documents can be found in electronic format

The following documents can be found under the Corporation's profile on SEDAR at www.sedar.com:

Arrangement Agreement and plan of merger dated June 28, 2024, among the Corporation, Sharp and Subco;

Amendment #1 to Arrangement Agreement dated October 31, 2024, as amended, among the Corporation, Sharp and Subco;

Merger Agreement among the Corporation, Sharp and Subco dated December 11, 2024;

Sponsorship Agreement among Canaccord Genuity Corp., Sharp and the Corporation dated December 10, 2024 and

Certificate and articles of arrangement and certificate and articles of amendment by arrangement of the Corporation dated December 11, 2024 in connection with the Arrangement.

DATED as of the 13th day of December, 2024.